Rituximab (RTX) Therapy in Patients With Active TAO
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Thyroid Associated Ophthalmopathy is condition affecting the eyes of about 10% of patients
with Graves disease. Its combination of protrusion affecting the looks of the patient and
pain is often severely affecting the quality of life among these patients.
The standard treatment for this illness today is intravenous glucocorticoids together with
methotrexate. The purpose of this study is to evaluate the effect of rituximab on patients
that do not respond to or relapse after conventional therapy.